Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
3.69 USD +1.65% Intraday chart for Journey Medical Corporation +8.53% -35.94%
01/05 Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer CI
21/03 Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JOURNEY MEDICAL CORPORATION Stock Journey Medical Corporation
-35.94% 72.5M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DERM Stock
  4. Ratings Journey Medical Corporation